Most RWE programmes fail because they’re built for scientists or payers, then retrofitted for the other. A strategy that works is engineered upfront to satisfy both – starting from the decisions the evidence needs to influence, not the data that happens to be available.
Those decisions extend beyond scientific and payer audiences to include regulators, clinicians, and internal teams, but this is where the misalignment is often most visible.
Why “good RWE” is no longer good enough
Real-world evidence (RWE) has become a cornerstone of modern evidence generation. For medical affairs, HEOR, and market access teams, it promises to answer questions that randomized clinical trials cannot: how treatments perform in routine practice, which patients benefit most, and what outcomes matter once a product leaves the controlled environment of a trial.
And yet, many organizations find themselves in a familiar bind. They generate RWE that is methodologically sound, passes internal scientific review, and even makes it into peer‑reviewed journals, but fails to move payer decisions. Or they produce payer‑relevant analyses that resonate commercially, only to be challenged by scientists, reviewers, or regulators on credibility.
The limitations of RWE programmes tend to stem less from execution issues and more from strategic misalignment. This misalignment is most apparent when evidence is expected to meet multiple sets of requirements it was not designed to address.
In today’s environment, real‑world evidence strategies must achieve multiple objectives simultaneously: generating robust data, withstanding scientific scrutiny, and answering the practical questions payers ask every day.
What a real-world evidence strategy actually is
A real-world evidence strategy is a decision‑driven plan for how RWE will be used across the asset lifecycle by regulators, payers, clinicians, and internal teams.
This reflects the range of uses RWE must support, from regulatory and clinical use through to access, adoption, and value communication.
A robust real-world evidence strategy defines:
- Which decisions the evidence is intended to influence
- Which stakeholders must be persuaded
- What constitutes credibility for each audience
- How evidence generation aligns with regulatory, access, and medical objectives
Crucially, this strategy must be designed upfront. Revisiting evidence plans after development or access decisions have been made almost always creates gaps between scientific rigor and payer relevance.
Study design choices made early on determine whether evidence will later be defensible to methodologists and meaningful to decision‑makers. Once those choices are locked in, no amount of statistical sophistication can compensate for a poorly framed question.
Why RWE must be designed around decisions from the outset
Many RWE strategies and programmes begin with data availability rather than decision need. Teams ask: What datasets do we have access to? What analyses are feasible?
The more important question is: What will a payer or HTA committee actually use this evidence for?
This sits alongside other use cases, including regulatory submissions, clinical adoption, and internal decision-making, which usually rely on the same underlying evidence base.
Payers evaluate real‑world evidence through the lens of specific decisions, asking questions such as:
- Does this therapy deliver meaningful benefit over existing options in routine care or clinical practice?
- Which patients derive value, and which do not?
- What are the budget and utilization implications under real‑world conditions?
If these questions are not built into the study design, the resulting evidence may be technically valid but strategically inert.
For example, a retrospective analysis may demonstrate strong outcomes versus historical controls and achieve publication in a peer-reviewed journal. However, if the comparator does not reflect current standard of care in a given market, HTA bodies may dismiss the findings as non-comparable. In this case, the issue is how the evidence aligns with payer decision frameworks.
An effective real-world evidence strategy therefore starts with decision context and works backwards to define the appropriate design, data sources, and methods.
The core tension: scientific rigor versus payer relevance
One of the most persistent challenges in implementing RWE strategies is the assumption that scientific credibility and payer relevance always align. In reality, they pull in different directions.
From a scientific perspective, credibility is driven by:
- Methodological transparency
- Control of bias and confounding (and wider data collection and data quality)
- Conservative assumptions
- Peer review acceptability
From a payer perspective, relevance is driven by:
- Comparability to the current standard of care
- Applicability to the covered population
- Clear economic or utilization implications
- Decision‑ready endpoints over exploratory findings
Both audiences value similar attributes, but the emphasis placed on different aspects can vary depending on the decision context.
A study optimized for publication may prioritize internal validity at the expense of generalizability. By contrast, a study optimized for access may focus on pragmatic outcomes that appear messy or imperfect to journal reviewers.
The role of a real‑world evidence strategy is to surface and manage these trade‑offs deliberately, so they are addressed explicitly as opposed to being left to emerge by default.
RWE study types, and when each actually makes sense
Different RWE study designs serve different strategic purposes. Problems occur when designs are chosen for familiarity instead of fitness for purpose.
Registry studies
Registry studies and registry research are valuable for understanding disease progression, treatment patterns, and long‑term outcomes. They can support both scientific and payer conversations, principally in areas of unmet need or rare disease, but require strong governance to ensure data consistency and relevance.
Observational cohort studies
These studies are well suited to comparative effectiveness questions and treatment sequencing analyses. When aligned with payer populations and treatment pathways, they can be highly influential – but only if comparators and endpoints reflect how decisions are made in practice.
Retrospective claims analyses
Claims data are habitually viewed with scepticism by scientists but are highly familiar to payers. Used well, they can facilitate compelling narratives around budget impact, adherence, and utilization. Used poorly, they raise questions about clinical validity and missing nuance.
Pragmatic trials
Pragmatic designs aim to bridge the gap between trials and practice. They can be resource‑intensive but offer a powerful way to generate evidence that satisfies both scientific and access requirements for high‑value or high‑scrutiny assets.
A mature real‑world evidence strategy deliberately sequences and combines different study designs based on the decisions each study is meant to support. This is most effective when those decisions are defined cross-functionally, rather than within individual teams.
Real-world data quality and data collection: credibility starts with provenance
Real‑world data are not interchangeable. Data source choice has a direct impact on how evidence is interpreted, and by whom.
- Claims data offer scale and longitudinal insight but limited clinical detail.
- Electronic health records provide richer clinical context but vary widely in completeness and consistency.
- Registries can offer depth and standardization but may lack representativeness.
- Patient‑reported outcomes bring critical patient voice but raise questions about bias and generalizability.
Scientific audiences focus on real-world data (RWD) validity, provenance, and missingness. Payers focus on representativeness and decision applicability. A sound real-world evidence strategy anticipates both perspectives and selects data accordingly, or combines sources where necessary.
How payers actually evaluate real-world evidence
Contrary to some assumptions, payers are not hostile to RWE. They are cautious, and for good reason. Many have seen evidence and solutions presented without a clear connection to their population or decision framework.
Payer evaluation tends to focus on:
- Relevance: does this reflect my covered lives?
- Comparability: does it mirror real alternatives?
- Transparency: are assumptions and limitations explicit?
- Actionability: does it inform a coverage or tiering decision?
Many RWE submissions struggle to influence payer decisions because the implications are not drawn out, leaving regulatory decision‑makers to derive relevance and impact for themselves.
Similar challenges can arise in regulatory or clinical contexts when findings are not clearly linked to how they will be used.
What does effective translation look like in practice?
- Clear linkage between study outcomes and coverage or formulary decisions
- Articulation of economic or utilization impact under real-world conditions
- Comparators and populations that mirror payer decision frameworks
RWE that requires interpretation is far less persuasive than evidence that directly informs action.
Pharmacovigilance and post‑marketing studies as strategic assets
Too often, pharmacovigilance and post‑marketing commitments are treated as regulatory obligations instead of strategic components of the real-world evidence strategy.
When aligned properly, safety studies, post‑authorization effectiveness studies, and ongoing monitoring can:
- Reinforce confidence in long‑term value
- Address residual payer uncertainty
- Generate data that feeds both medical and access narratives
The key is integration. Evidence generated for safety compliance should not live in isolation from broader evidence planning.
Regulatory frameworks, and why they still matter for access
Regulatory guidance, particularly from the FDA, shapes what is considered acceptable RWE. While payer standards are not identical to regulatory ones, they overlap significantly in expectations around transparency, data fitness, and methodological soundness.
A real-world evidence strategy that ignores regulatory guidance risks creating evidence that is difficult to defend under scrutiny, even if it appears commercially compelling.
The strongest strategies anticipate regulatory expectations and payer use cases, rather than treating them as separate tracks.
Building an RWE strategy that serves multiple stakeholders
Serving regulators, payers, clinicians, and patients requires prioritizing decisions and designing evidence that travels – with clarity – across audiences. This depends on early alignment across functions on what the evidence is expected to support and how it will be used.
Practically, this necessitates:
- Articulation of trade‑offs
- Governance that protects scientific integrity without paralyzing action
- Medical affairs leadership that understands access realities, not just publication goals
What best‑in‑class RWE capability looks like
Leading organizations treat RWE as a strategic capability embedded across the business. They invest in:
- Clear ownership and governance
- Integrated evidence planning across functions
- Reusable data and analytic infrastructure
- Evidence generation designed to support decisions at critical points in the asset lifecycle
Most importantly, they view real-world evidence strategy as a bridge, connecting science to access, and insight to impact. That bridge extends across regulatory, clinical, and access contexts, requiring consistency in how evidence is generated, interpreted, and applied.
Frequently asked questions (FAQs) about RWE strategy
What is a real-world evidence strategy?
A real-world evidence strategy is a decision‑focused plan for generating, analyzing, and applying RWE to support regulatory, payer, clinical, and internal decisions across the product lifecycle.
Why do payers reject real-world evidence?
Most rejections stem from relevance issues: mismatched populations, inappropriate comparators, or unclear decision implications, rather than methodology alone.
Can RWE satisfy both scientific and payer standards?
Yes, but only when trade‑offs are identified early and designed for intentionally.
How does medical affairs fit into RWE strategy?
Medical affairs plays a critical role in connecting scientific credibility with real‑world applicability, ensuring evidence is trusted anduseful.
Contact us
